$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
瑞博西利对于转移性乳腺癌患者是个不错的选择
2025-10-19 11:44:20
Check Details
瑞博西林治疗晚期乳腺癌的疗效分析及不良反应
2025-10-19 11:44:20
Check Details
乳腺癌患者使用瑞博西利需要阅读的药品说明书
2025-10-19 11:44:20
Check Details
乳腺癌患者服用瑞博西林的禁忌和注意事项
2025-10-19 11:44:20
Check Details
瑞博西利是帕博西尼耐药后的治疗选择吗?
2025-10-19 11:44:20
Check Details
瑞博西林可以作为晚期乳腺癌的一线治疗用药吗?
2025-10-19 11:44:20
Check Details
CDK4/6抑制剂瑞博西利经FDA批准的适应症有哪些?
2025-10-19 11:44:20
Check Details
什么情况下可以采用CDK4/6抑制剂瑞博西林进行治疗?
2025-10-19 11:44:20
Check Details
瑞博西林在治疗HR+/HER2晚期或转移性乳腺癌这方面有着显著的疗效
2025-10-19 11:44:20
Check Details
瑞博西林对于晚期HER2阳性乳腺癌可显著延长患者总生存期
2025-10-19 11:44:20
Check Details
晚期乳腺癌一线治疗用药:CDK4/6抑制剂瑞博西利
2025-10-19 11:44:20
Check Details
乳腺癌患者如何正确使用瑞博西林进行治疗?
2025-10-19 11:44:20
Check Details
1
2
...
1999
2000
2001
2002
2003
2004
2005
...
4159
4160
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Sotorasib (Lumakras): A Comprehensive Guide to the First KRAS G12C-Targeted Inhibitor
2
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
3
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
4
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
5
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
6
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
7
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
8
Lapatinib: Proper Administration Guide and Key Precautions
9
Capivasertib (Truqap) Complete Medication Guide: Indications, Dosing, Safety, and Precautions
10
Cemiplimab Storage and Handling Guide
11
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
12
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring